Cargando…
Erythropoietin Mediated Bone Loss in Mice Is Dose-Dependent and Mostly Irreversible
Recent studies have demonstrated that erythropoietin (EPO) treatment in mice results in trabecular bone loss. Here, we investigated the dose-response relationship between EPO, hemoglobin (Hgb) and bone loss and examined the reversibility of EPO-induced damage. Increasing doses of EPO over two weeks...
Autores principales: | Kolomansky, Albert, Hiram-Bab, Sahar, Ben-Califa, Nathalie, Liron, Tamar, Deshet-Unger, Naamit, Mittelman, Moshe, Oster, Howard S., Rauner, Martina, Wielockx, Ben, Neumann, Drorit, Gabet, Yankel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312352/ https://www.ncbi.nlm.nih.gov/pubmed/32471308 http://dx.doi.org/10.3390/ijms21113817 |
Ejemplares similares
-
Erythropoietin receptor in B cells plays a role in bone remodeling in mice
por: Deshet-Unger, Naamit, et al.
Publicado: (2020) -
Erythropoietin treatment in murine multiple myeloma: immune gain and bone loss
por: Deshet-Unger, Naamit, et al.
Publicado: (2016) -
Erythropoietin enhances Kupffer cell number and activity in the challenged liver
por: Gilboa, Dafna, et al.
Publicado: (2017) -
Anti-CD20-Mediated B Cell Depletion Is Associated With Bone Preservation in Lymphoma Patients and Bone Mass Increase in Mice
por: Kolomansky, Albert, et al.
Publicado: (2020) -
Erythropoietin Receptor (EPOR) Signaling in the Osteoclast Lineage Contributes to EPO-Induced Bone Loss in Mice
por: Awida, Zamzam, et al.
Publicado: (2022)